Acamprosate
- Generic Name
- Acamprosate
- Brand Names
- Campral
- Drug Type
- Small Molecule
- Chemical Formula
- C5H11NO4S
- CAS Number
- 77337-76-9
- Unique Ingredient Identifier
- N4K14YGM3J
- Background
Alcohol use disorder is responsible for a large worldwide burden of morbidity, premature mortality, and economic consequences resulting from accidents, violence, incarceration, decreased productivity, and increased healthcare spending.
Acamprosate, also known by the brand name Campral, is a drug used for the maintenance of alcohol abstinence. It is a structural analogue of the neurotransmitter γ-aminobutyric acid (GABA). Acamprosate is the first medication specifically formulated for the maintenance of alcohol abstinence in ethanol-dependent patients after alcohol detoxification, unlike naltrexone and disulfiram. It was first approved by the FDA in 2004 and initially marketed by Forest Laboratories.
- Indication
Acamprosate is indicated for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation. It is also indicated for the maintenance of alcohol abstinence in patients who have undergone alcohol detoxification. This drug should be used with a psychosocial support program providing adequate support.
- Associated Conditions
- Alcohol Abstinence, Alcohol Dependency
Modulation of Pharmacologically Induced Alcohol Craving in Recently Detoxified Alcoholics
- Conditions
- Alcoholism
- Interventions
- First Posted Date
- 2008-01-31
- Last Posted Date
- 2012-07-03
- Lead Sponsor
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- Target Recruit Count
- 37
- Registration Number
- NCT00605904
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Clinical Trial of Acamprosate for Tinnitus
- First Posted Date
- 2008-01-17
- Last Posted Date
- 2016-11-08
- Lead Sponsor
- Oregon Health and Science University
- Target Recruit Count
- 154
- Registration Number
- NCT00596531
- Locations
- 🇺🇸
OHSU, Portland, Oregon, United States
An 8 Week Open-Label Study to Evaluate the Efficacy and Safety of Acamprosate Calcium (Campral) as Augmentation Therapy in Patients With Anxiety Symptoms Who Are Only Partial Responders to SSRI or SNRI Antidepressants
- First Posted Date
- 2008-01-11
- Last Posted Date
- 2014-12-18
- Lead Sponsor
- State University of New York - Upstate Medical University
- Target Recruit Count
- 13
- Registration Number
- NCT00591565
- Locations
- 🇺🇸
SUNY Upstate Medical University Psychiatry Dept., Syracuse, New York, United States
A Clinical Trial of Acamprosate for Treatment of Methamphetamine Addiction
- Conditions
- Methamphetamine Dependence, Treatment Seeking
- Interventions
- Drug: placebo
- First Posted Date
- 2007-12-12
- Last Posted Date
- 2017-03-24
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 72
- Registration Number
- NCT00571922
- Locations
- 🇺🇸
VA New York Harbor Healthcare System, MHAD clinic, New York, New York, United States
Acamprosate in the Treatment of Pathological Gambling
- First Posted Date
- 2007-12-11
- Last Posted Date
- 2017-05-25
- Lead Sponsor
- University of Iowa
- Target Recruit Count
- 26
- Registration Number
- NCT00571103
Acamprosate in the Treatment of Binge-Eating Disorder
- First Posted Date
- 2007-08-06
- Last Posted Date
- 2011-06-22
- Lead Sponsor
- Lindner Center of HOPE
- Target Recruit Count
- 40
- Registration Number
- NCT00511940
- Locations
- 🇺🇸
Lindner Center of HOPE, Mason, Ohio, United States
Acamprosate vs. Placebo in Bipolar Alcoholics
- Conditions
- Alcohol DependenceBipolar Disorder
- Interventions
- Drug: Placebo
- First Posted Date
- 2007-04-27
- Last Posted Date
- 2018-12-14
- Lead Sponsor
- Medical University of South Carolina
- Target Recruit Count
- 33
- Registration Number
- NCT00466661
- Locations
- 🇺🇸
Institute of Psychiatry, Medical University of South Carolina, Charleston, South Carolina, United States
Treatment With Acamprosate in Patients With Schizophrenia and Comorbid Alcoholism
- Conditions
- Alcohol DependenceSchizophrenia
- Interventions
- Drug: Placebo
- First Posted Date
- 2007-04-20
- Last Posted Date
- 2020-03-31
- Lead Sponsor
- Yale University
- Target Recruit Count
- 23
- Registration Number
- NCT00463346
- Locations
- 🇺🇸
VA Connecticut Healthcare System, West Haven, Connecticut, United States
Acamprosate Added to Escitalopram and Behavioral Treatment for Comorbid Depression and Alcoholism
- Conditions
- Major Depressive DisorderAlcohol AbuseAlcohol Dependence
- Interventions
- First Posted Date
- 2007-03-27
- Last Posted Date
- 2012-07-09
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 23
- Registration Number
- NCT00452543
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Comparative Trial Of Disulfiram, Naltrexone And Acamprosate In The Treatment Of Alcohol Dependence
- Conditions
- Alcohol Dependence
- First Posted Date
- 2007-02-15
- Last Posted Date
- 2007-02-16
- Lead Sponsor
- Finnish Institute for Health and Welfare
- Target Recruit Count
- 243
- Registration Number
- NCT00435435
- Locations
- 🇫🇮
National Public Health Institute, Department of Mental Health and Alcohol Research, Helsinki, Finland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.